CG Oncology

About CG Oncology

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing oncolytic immunotherapies for patients with bladder cancer. Its pipeline includes investigational therapies such as BOND-003, CORE-001, CORE-002, PIVOT-006, and CORE-008, targeting high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer. The company’s lead candidate, cretostimogene grenadenorepvec, is an engineered oncolytic immunotherapy evaluated as both monotherapy and in combination with checkpoint inhibitors. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and is headquartered in Irvine, California.